Pharmacokinetics of lithium in patients treated with controlled release lithium formulations.
There has long been discussion as to the relative merits of the lithium formulations available in the UK. Two of these have been shown to exhibit similar pharmacokinetics in normal volunteers and both are now marketed as controlled release formulations. In this study the serum lithium profiles of these formulations were compared in patients at two centres during the first 4 h after the dose, and at 24 h. We were unable to show any significant difference between the formulations in respect of maximum serum lithium concentrations or the concentration at each time point.
Phillips
J D
JD
Royal Shrewsbury Hospital, Shelton, UK.
Myers
D H
DH
King
J R
JR
Armond
A D
AD
Derham
C
C
Puranik
A
A
Corbett
J A
JA
Birch
N J
NJ
D000328:Adult; D000368:Aged; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D008094:Lithium / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D008297:Male; D008875:Middle Aged; D019964:Mood Disorders / Q000097:blood / Q000188:drug therapy*
D003692:Delayed-Action Preparations; D008094:Lithium